Entresto is a first-in-class angiotensin receptor/neprilysin inhibitor consisting of valsartan and sacubitril. Valsartan is an angiotensin receptor blocker (ARB) that competes with angiotensin II for binding to the AT1 receptor, while sacubitril is a prodrug that inhibits neprilysin, an enzyme responsible for the breakdown of several vasoactive peptides. The combined action of both molecules attenuates vasoconstriction and sodium retention, helping to improve the underlying pathology of chronic heart failure.
LIST OF FIGURES
10 Figure 1: Entresto for chronic heart failure – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Entresto for chronic heart failure
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Entresto for chronic heart failure
17 Figure 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Entresto drug profile
6 Table 2: Entresto Phase III data in chronic heart failure
8 Table 3: Ongoing pivotal trials for Entresto in chronic heart failure
18 Table 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.